A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson Cancer Center.
An assessment of the alternative research model was published in the May 14 online issue of Cancer. The model was piloted in a multi-study leukemia research program established between MD Anderson...
Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to...
The University of Texas MD Anderson Cancer Center and Spectrum Pharmaceuticals have signed a licensing agreement that covers discoveries by...